Idera Pharmaceuticals, Inc. (IDRA)
$0.425
-0.13 (-23.04%)
Rating:
Recommendation:
Buy
| Symbol | IDRA |
|---|---|
| Price | $0.425 |
| Beta | 0.000 |
| Volume Avg. | 0.03M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 0.4201-16.0 |
| 1y Target Est | - |
| DCF Unlevered | IDRA DCF -> | |
|---|---|---|
| DCF Levered | IDRA LDCF -> | |
| ROE | -117.43% | Strong Sell |
| ROA | -23.10% | Sell |
| Operating Margin | - | |
| Debt / Equity | 4.74% | Neutral |
| P/E | - | |
| P/B | 0.12 | Neutral |
Latest IDRA news
About
Download (Excel)Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.